Immunomodulating agents (ImiDs) are a novel class of anticancer drugs that have demonstrated impressive antitumor activity in various malignant disorders. Of this class, most recent research has been focused on the remarkably active agent, lenalidomide. Lenalidomide was designed to enhance immunologic and anticancer properties while potentially decreasing neurotoxic and teratogenic adverse effects of the parent compound thalidomide.

The introduction of this novel agent has broadened the therapeutic landscape of hematologic malignant disorders including Multiple Myeloma (MM) and, more recently, other B-cell neoplasms.

In this issue, we will focus on mechanisms of action and results from clinical investigation that report the relevance of lenalidomide for the treatment of B-cell disorders including MM, Chronic Lymphocytic Leukaemia (CLL), and Non-Hodgkin's lymphomas by offering new mechanisms for targeting these diseases.

In particular, manuscripts defining the role of lenalidomide as part of the induction therapy before Hematopoietic Stem Cells Transplantation (HSCT) as well as its use as extended maintenance therapy post-HSTC in patients with MM will be of great interest.

Moreover, we will welcome papers emphasizing the efficacy of lenalidomide used alone or in combination with other agents for the chemotherapy of Mantle cell and low-grade lymphomas as well as in association with chemoimmunotherapy as a therapeutic strategy in patients with diffuse large B-cell lymphomas.

Finally, manuscripts regarding clinical safety and/either efficacy of the use of lenalidomide as single agent or as in combination with conventional or biological drugs in patients with CLL will be acknowledged. Potential topics include, but are not limited to:

• Lenalidomide: mechanism of action
• Lenalidomide as part of the induction therapy before HSCT and its use as consolidation and maintenance therapy of multiple myeloma
• Lenalidomide in chronic lymphocytic leukaemia
• Lenalidomide in diffuse large B-cell lymphoma
• Lenalidomide in Mantle cell and low-grade Non-Hodgkin's lymphomas

Before submission authors should carefully read over the journal's Author Guidelines, which are located at http://www.hindawi.com/journals/ah/guidelines/. Prospective authors should submit an electronic copy of their complete manuscript through the journal Manuscript Tracking System at http://mts.hindawi.com/ according to the following timetable: